Strides Arcolab announced a collaboration with Pfizer, USA on Thursday where Pfizer will commercialise the later's off-patent sterile injectables and oral products in the US.
These finished dosage form products will be licensed and supplied by Strides and two South Africa-based JVs of Strides where Strides holds 50%.
Pfizer will commercialise around 40 off-patent products in the oncology area. The first product will be launched this year.